• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center
 

Member Resources

Pipelines in Oncology

December 15, 2005 - Biogen Idec

http://www.biogenidec.com/

Burt Adleman, MD - Executive Vice President, Development:

Presentation on:

  • Anti-CD80
  • Anti-CD23
  • Anti-LTbR
  • Volociximab
  • Anti-avb6
  • Anti-BR3 mAb
  • BAFF-Receptor Fc
  • ADIFNb
  • Anti-CRIPTO Toxin conjugated mAb
  • Early Stage Programs


November 10, 2005 - Eli Lilly

http://www.lilly.com/

Christopher Slapak, MD -  Medical Research Fellow (Executive Director), Cancer Research and Clinical Investigation
Richard Gaynor, MD - VP Cancer Research and Clinical Investigation

Presentation on:

  • Enzastaurin Hydrochloride, orally active small-molecule inhibitor of protein kinase C (PKC) beta
  • Survivin antisense oligonucleotide (ASO)
  • TGF beta-receptor kinase inhibitors
  • ASAP, a novel cytotoxic that induces apoptosis


October 20, 2005 - Kosan Biosciences

http://www.kosan.com/

Robert Johnson, MD - Executive VP, Development

Presentation on:

  • KOS-862 (Epothilone D) and KOS-1584, microtubule stabilizers
  • KOS-953 (17-AAG) and KOS-1022 (DMAG), Hsp90 inhibitors
  • KOS-1815, an inhibitor of CRM1 nuclear transport export processes
  • KOS-2186, a novel MEK kinase pathway inhibitor


September 8, 2005 - Wyeth

http://www.wyeth.com

Lee Allen, MD - Cambridge Site Head, Vice President, Medical Research, Oncology Therapeutic Area

Presentation on:

  • Temsirolimus, an mTOR kinase inhibitor
  • HKI-272, an irreversible pan-erB kinase inhibitor
  • SKI-606, an orally active src kinase inhibitor
  • MKI-833, an oral, reversible MEK kinase inhibitor
  • CMC-544 and CMD-193, both monoclonal antibody targeted chemotherapy
  • MST-997 and TTI-237, both microtubule inhibitors


June 9, 2005 - Sanofi-Aventis

http://en.sanofi-aventis.com/

Sunil Gupta, MD - Senior Director, Clinical Development Oncology

Presentation on:

  • Tirapazimine
  • XRP9881
  • Xaliproden
  • Alvocidib
  • SR31747
  • UVIDEM
  • XRP6258
  • SSR125329


May 19, 2005 - GlaxoSmithKline

http://www.gsk.com/

Peter Ho, MD - VP, Discovery Medicine - Oncology
Allen Oliff, MD -  Senior Vice President MMPD CEDD

Presentation on:

  • Lapatinib, a dual erb-b kinase inhibitor
  • GSK VEGF-R kinase inhibitor
  • IL-18 cytokine for immunologically sensitive tumors
  • TPO, an oral agent for thrombocytopenias
  • NK-1 antagonist for emesis control
  • Cathepsin-K inhibitor for metastasis control
  • Pre-clinical pipeline of kinase targets and nucleoside analogs